Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma

Cancer

Volumn 116, Issue 1, 2010, Pages 84-92

  Ailawadhi, Sikander ^a   Abdelhalim, Ahmed N ^a   Derby, Lyudmyla ^a   Mashtare, Terry L ^a   Miller, Kena C ^a   Wilding, Gregory E ^a   Alberico, Ronald A ^a   Gottlieb, Ronald ^a   Klippenstein, Donald L ^a   Lee, Kelvin ^a   Chanan Khan, Asher A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Disease burden; Magnetic resonance imaging; Multiple myeloma; Survival

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER STAGING; CLINICAL EVALUATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMACYTOSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 74549162706     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24704     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
3. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 1. 2008. Fort Washington, Pa: National Comprehensive Cancer Network, Inc; 2007. Available at http://www.nccn.org. Accessed January 2009.
4. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007; 82:323-341.
5. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625-1634.
6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
7. Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol. 1985;74:27-30.
8. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood. 1997;90:2127-2147.
9. Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol. 2005;16:1824-1828.
10. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology. 1994;193:441-446.
11. Fonti R, Salvatore B, Quarantelli M, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med. 2008;49:195-200.
12. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50-55.
13. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
14. International Myeloma Working Group.Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
15. Dytfeld D, Sosnowski P, Czyz A, Komarnick M. [The role of the magnetic resonance in diagnosis of multiple myeloma]. Pol Merkur Lekarski. 2007;23:85-88.
16. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121-1128.
17. Fruehwald FX, Tscholakoff D, Schwaighofer B, et al. Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma. Invest Radiol. 1988;23: 193-199.
18. Daffner RH, Lupetin AR, Dash N, Deeb ZL, Sefczek RJ, Schapiro RL. MRI in the detection of malignant infiltration of bone marrow. AJR Am J Roentgenol. 1986;146:353-358.
19. Moulopoulos LA, Varma DG, Dimopoulos MA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology. 1992;185:833-840.
20. Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 1995;13:251-256.
21. Libshitz HI, Malthouse SR, Cunningham D, MacVicar AD, Husband JE. Multiple myeloma: appearance at MR imaging. Radiology. 1992;182:833-837.
22. Rahmouni A, Divine M, Mathieu D, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. AJR Am J Roentgenol. 1993;160:1049-1052.
23. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003; 17:427-436.
24. Matsui S, Yamanaka T, Barlogie B, Shaughnessy JD Jr, Crowley J. Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma. Stat Med. 2008;27:1106-1120.
25. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008;111:968-969.
26. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
27. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol. 2007;20:625-635.
28. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109:3489-3495.